Aducanumab: A Deep Dive into BIIB037 and its Impact The drug, previously known as BIIB037, represents a complex endeavor to treat mild Alzheimer's condition. Developed by Biogen, the treatment functions by clearing https://www.targetmol.com/compound/aducanumab